Related Experiment Video
Updated: Aug 25, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Thrombolytic therapy for acute ischaemic stroke
1Royal Bournemouth and Christchurch Hospitals NHS Trust, Christchurch BH23 2JX.
Recombinant tissue plasminogen activator (rt-PA, also known as alteplase; Actilyse) is the first and only licensed thrombolytic approved for use in acute ischaemic stroke in the UK. This article reviews the evidence for the role of rt-PA in acute stroke management and how it may improve long-term clinical outcome for selected patients as part of a comprehensive stroke service.
Recombinant tissue plasminogen activator (rt-PA, also known as alteplase; Actilyse) is the first and only licensed thrombolytic approved for use in acute ischaemic stroke in the UK. This article reviews the evidence for the role of rt-PA in acute stroke management and how it may improve long-term clinical outcome for selected patients as part of a comprehensive stroke service.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Ischemic Stroke l: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Ischemic Stroke ll: Pathophysiology
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Transient Ischemic Attack l: Introduction

